Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease
Identifieur interne : 000804 ( Istex/Corpus ); précédent : 000803; suivant : 000805Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease
Auteurs : Terecita D. Yule ; Mark B. Roth ; Kimberly Dreier ; Anthony F. Johnson ; Melissa Palmer-Densmore ; Kris Simmons ; Robert FantonSource :
- Vaccine [ 0264-410X ] ; 1997.
English descriptors
- Teeft :
- Acute phase proteins, Acute phase reactants, Acute phase response, Assay, Canine, Canine neutrophils, Canine parvovirus, Canine parvovirus enteritis, Canine parvovirus type, Canine parvovirus vaccine, Cell count, Cell counts, Cell surface proteins, Clinical consequences, Clinical disease, Clinical manifestations, Clinical scores, Clinical signs, Control group, Control puppies, Control standards, Cpv3b challenge, Crypt cells, Cytometric, Cytometry, Days post challenge figure, Dose vaccine regimen, Elsevier science, Experimental challenge, Experimental infection, First vaccination, Flow buffer, Flow cytometric, Flow cytometric analysis, Flow cytometry, Immunol, Indirect effect, Individual animals, Inflammation, John wiley, Leukocyte, Leukocyte phenotypes, Leukocyte trafficking, Lymphocyte, Lymphopenia, Major capsid protein, Microtiter plates, Monoclonal antibodies, Natural infection, Natural infections, Neutropenia, Neutrophil, Neutrophil function, Neutrophilia, Nonvaccinated, Nonvaccinated controls, Observation period, Parvovirus, Parvovirus infection, Peripheral blood, Puppies seroconverted, Puppy, Second vaccination, Seropositive puppies, Serum amyloid, Significant deviation, Solid line, Solid lines, Third vaccination, Tissue antigens, Tissue damage, Titer, Total leukocyte count, Trafficking, Vaccinated, Vaccinated puppies, Vaccinates, Vaccination, Vaccine, Vaccine efficacy, Vascular endothelium, Virus infection, Virus recovery, Yule.
Abstract
Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.
Url:
DOI: 10.1016/S0264-410X(96)00232-0
Links to Exploration step
ISTEX:ED82901CC45CF7E00C6B3215F1A3E36841490C1FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title><author><name sortKey="Yule, Terecita D" sort="Yule, Terecita D" uniqKey="Yule T" first="Terecita D." last="Yule">Terecita D. Yule</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Roth, Mark B" sort="Roth, Mark B" uniqKey="Roth M" first="Mark B." last="Roth">Mark B. Roth</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Dreier, Kimberly" sort="Dreier, Kimberly" uniqKey="Dreier K" first="Kimberly" last="Dreier">Kimberly Dreier</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Johnson, Anthony F" sort="Johnson, Anthony F" uniqKey="Johnson A" first="Anthony F." last="Johnson">Anthony F. Johnson</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Palmer Densmore, Melissa" sort="Palmer Densmore, Melissa" uniqKey="Palmer Densmore M" first="Melissa" last="Palmer-Densmore">Melissa Palmer-Densmore</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Simmons, Kris" sort="Simmons, Kris" uniqKey="Simmons K" first="Kris" last="Simmons">Kris Simmons</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Fanton, Robert" sort="Fanton, Robert" uniqKey="Fanton R" first="Robert" last="Fanton">Robert Fanton</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:ED82901CC45CF7E00C6B3215F1A3E36841490C1F</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0264-410X(96)00232-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000804</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000804</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title><author><name sortKey="Yule, Terecita D" sort="Yule, Terecita D" uniqKey="Yule T" first="Terecita D." last="Yule">Terecita D. Yule</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Roth, Mark B" sort="Roth, Mark B" uniqKey="Roth M" first="Mark B." last="Roth">Mark B. Roth</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Dreier, Kimberly" sort="Dreier, Kimberly" uniqKey="Dreier K" first="Kimberly" last="Dreier">Kimberly Dreier</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Johnson, Anthony F" sort="Johnson, Anthony F" uniqKey="Johnson A" first="Anthony F." last="Johnson">Anthony F. Johnson</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Palmer Densmore, Melissa" sort="Palmer Densmore, Melissa" uniqKey="Palmer Densmore M" first="Melissa" last="Palmer-Densmore">Melissa Palmer-Densmore</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Simmons, Kris" sort="Simmons, Kris" uniqKey="Simmons K" first="Kris" last="Simmons">Kris Simmons</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author><author><name sortKey="Fanton, Robert" sort="Fanton, Robert" uniqKey="Fanton R" first="Robert" last="Fanton">Robert Fanton</name><affiliation><mods:affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">6–7</biblScope><biblScope unit="page" from="720">720</biblScope><biblScope unit="page" to="729">729</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute phase proteins</term><term>Acute phase reactants</term><term>Acute phase response</term><term>Assay</term><term>Canine</term><term>Canine neutrophils</term><term>Canine parvovirus</term><term>Canine parvovirus enteritis</term><term>Canine parvovirus type</term><term>Canine parvovirus vaccine</term><term>Cell count</term><term>Cell counts</term><term>Cell surface proteins</term><term>Clinical consequences</term><term>Clinical disease</term><term>Clinical manifestations</term><term>Clinical scores</term><term>Clinical signs</term><term>Control group</term><term>Control puppies</term><term>Control standards</term><term>Cpv3b challenge</term><term>Crypt cells</term><term>Cytometric</term><term>Cytometry</term><term>Days post challenge figure</term><term>Dose vaccine regimen</term><term>Elsevier science</term><term>Experimental challenge</term><term>Experimental infection</term><term>First vaccination</term><term>Flow buffer</term><term>Flow cytometric</term><term>Flow cytometric analysis</term><term>Flow cytometry</term><term>Immunol</term><term>Indirect effect</term><term>Individual animals</term><term>Inflammation</term><term>John wiley</term><term>Leukocyte</term><term>Leukocyte phenotypes</term><term>Leukocyte trafficking</term><term>Lymphocyte</term><term>Lymphopenia</term><term>Major capsid protein</term><term>Microtiter plates</term><term>Monoclonal antibodies</term><term>Natural infection</term><term>Natural infections</term><term>Neutropenia</term><term>Neutrophil</term><term>Neutrophil function</term><term>Neutrophilia</term><term>Nonvaccinated</term><term>Nonvaccinated controls</term><term>Observation period</term><term>Parvovirus</term><term>Parvovirus infection</term><term>Peripheral blood</term><term>Puppies seroconverted</term><term>Puppy</term><term>Second vaccination</term><term>Seropositive puppies</term><term>Serum amyloid</term><term>Significant deviation</term><term>Solid line</term><term>Solid lines</term><term>Third vaccination</term><term>Tissue antigens</term><term>Tissue damage</term><term>Titer</term><term>Total leukocyte count</term><term>Trafficking</term><term>Vaccinated</term><term>Vaccinated puppies</term><term>Vaccinates</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine efficacy</term><term>Vascular endothelium</term><term>Virus infection</term><term>Virus recovery</term><term>Yule</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>neutrophil</json:string><json:string>parvovirus</json:string><json:string>canine</json:string><json:string>lymphocyte</json:string><json:string>leukocyte</json:string><json:string>vaccine</json:string><json:string>vaccinated</json:string><json:string>vaccinates</json:string><json:string>puppy</json:string><json:string>acute phase proteins</json:string><json:string>yule</json:string><json:string>neutropenia</json:string><json:string>clinical manifestations</json:string><json:string>cytometric</json:string><json:string>cytometry</json:string><json:string>nonvaccinated</json:string><json:string>clinical signs</json:string><json:string>lymphopenia</json:string><json:string>neutrophilia</json:string><json:string>trafficking</json:string><json:string>flow cytometry</json:string><json:string>canine parvovirus vaccine</json:string><json:string>clinical scores</json:string><json:string>immunol</json:string><json:string>nonvaccinated controls</json:string><json:string>canine parvovirus</json:string><json:string>inflammation</json:string><json:string>observation period</json:string><json:string>clinical disease</json:string><json:string>flow cytometric analysis</json:string><json:string>control puppies</json:string><json:string>leukocyte trafficking</json:string><json:string>control group</json:string><json:string>vaccinated puppies</json:string><json:string>experimental challenge</json:string><json:string>serum amyloid</json:string><json:string>experimental infection</json:string><json:string>assay</json:string><json:string>vaccination</json:string><json:string>acute phase response</json:string><json:string>first vaccination</json:string><json:string>cell count</json:string><json:string>flow cytometric</json:string><json:string>monoclonal antibodies</json:string><json:string>solid line</json:string><json:string>parvovirus infection</json:string><json:string>canine parvovirus enteritis</json:string><json:string>seropositive puppies</json:string><json:string>flow buffer</json:string><json:string>titer</json:string><json:string>john wiley</json:string><json:string>dose vaccine regimen</json:string><json:string>microtiter plates</json:string><json:string>natural infection</json:string><json:string>major capsid protein</json:string><json:string>cell counts</json:string><json:string>control standards</json:string><json:string>puppies seroconverted</json:string><json:string>second vaccination</json:string><json:string>crypt cells</json:string><json:string>acute phase reactants</json:string><json:string>canine parvovirus type</json:string><json:string>solid lines</json:string><json:string>individual animals</json:string><json:string>third vaccination</json:string><json:string>vaccine efficacy</json:string><json:string>cell surface proteins</json:string><json:string>days post challenge figure</json:string><json:string>significant deviation</json:string><json:string>cpv3b challenge</json:string><json:string>peripheral blood</json:string><json:string>leukocyte phenotypes</json:string><json:string>virus infection</json:string><json:string>natural infections</json:string><json:string>neutrophil function</json:string><json:string>indirect effect</json:string><json:string>canine neutrophils</json:string><json:string>vascular endothelium</json:string><json:string>tissue damage</json:string><json:string>elsevier science</json:string><json:string>clinical consequences</json:string><json:string>total leukocyte count</json:string><json:string>tissue antigens</json:string><json:string>virus recovery</json:string></teeft></keywords><author><json:item><name>Terecita D. Yule</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item><json:item><name>Mark B. Roth</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item><json:item><name>Kimberly Dreier</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item><json:item><name>Anthony F. Johnson</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item><json:item><name>Melissa Palmer-Densmore</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item><json:item><name>Kris Simmons</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item><json:item><name>Robert Fanton</name><affiliations><json:string>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>canine parvovirus vaccine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>acute phase proteins</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>leukopenia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CD4-neutrophil</value></json:item></subject><arkIstex>ark:/67375/6H6-3H03FGMF-Q</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.</abstract><qualityIndicators><score>7.99</score><pdfWordCount>4622</pdfWordCount><pdfCharCount>33901</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>576 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>114</abstractWordCount><abstractCharCount>859</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title><pmid><json:string>9178474</json:string></pmid><pii><json:string>S0264-410X(96)00232-0</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>1997</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0039-4</json:string></pii><volume>15</volume><issue>6–7</issue><pages><first>720</first><last>729</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1997</json:string></date><geogName></geogName><orgName><json:string>University of Nebraska Medical Center</json:string><json:string>BWEF Inc.</json:string><json:string>Sigma Chemical Co</json:string><json:string>National Veterinary Services Laboratory, Ames, IA</json:string><json:string>Biosource International</json:string><json:string>Roche Diagnostics</json:string><json:string>Millipore Corporation</json:string><json:string>Developmental Technologies</json:string><json:string>Kierkegaard and Perry International</json:string><json:string>Central Research Diyision, Pfizer Inc</json:string><json:string>Pfizer, Inc.</json:string><json:string>Elsevier Science Ltd</json:string><json:string>Pfizer Central Research, Katrina Kokjohn and Kathy</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Manuel Campos</json:string><json:string>S.D. Differences</json:string><json:string>Mary Ann</json:string><json:string>William C. Davis</json:string><json:string>F. Johnson</json:string><json:string>Robert Fanton</json:string><json:string>Marta Sabara</json:string><json:string>David Keller</json:string><json:string>Kimberly Dreier</json:string><json:string>Annika Weber</json:string><json:string>Kris Simmons</json:string><json:string>David Brake</json:string><json:string>T.L. McDonald</json:string><json:string>Thomas</json:string><json:string>Mark B. Roth</json:string><json:string>Melissa Palmer-Densmore</json:string></persName><placeName><json:string>Bedford</json:string><json:string>NE.</json:string><json:string>Lakewood</json:string><json:string>Camarillo</json:string><json:string>United States</json:string><json:string>Burlington</json:string><json:string>Frederick</json:string><json:string>NC</json:string><json:string>Gaithersburg</json:string><json:string>MD</json:string><json:string>NE</json:string><json:string>CA</json:string><json:string>MA</json:string><json:string>Mountain View</json:string><json:string>Omaha</json:string><json:string>Lincoln</json:string><json:string>PA</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Yule et al.</json:string><json:string>Yule et al. 6001</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-3H03FGMF-Q</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pathologie osteoarticulaire</json:string></inist></categories><publicationDate>1997</publicationDate><copyrightDate>1997</copyrightDate><doi><json:string>10.1016/S0264-410X(96)00232-0</json:string></doi><id>ED82901CC45CF7E00C6B3215F1A3E36841490C1F</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1997</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title><author xml:id="author-0000"><persName><forename type="first">Terecita D.</forename><surname>Yule</surname></persName><affiliation>To whom correspondence should be addressed.</affiliation><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Mark B.</forename><surname>Roth</surname></persName><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Kimberly</forename><surname>Dreier</surname></persName><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Anthony F.</forename><surname>Johnson</surname></persName><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Melissa</forename><surname>Palmer-Densmore</surname></persName><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Kris</forename><surname>Simmons</surname></persName><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Robert</forename><surname>Fanton</surname></persName><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation></author><idno type="istex">ED82901CC45CF7E00C6B3215F1A3E36841490C1F</idno><idno type="ark">ark:/67375/6H6-3H03FGMF-Q</idno><idno type="DOI">10.1016/S0264-410X(96)00232-0</idno><idno type="PII">S0264-410X(96)00232-0</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0039-4</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997"></date><biblScope unit="volume">15</biblScope><biblScope unit="issue">6–7</biblScope><biblScope unit="page" from="720">720</biblScope><biblScope unit="page" to="729">729</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1997</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>canine parvovirus vaccine</term></item><item><term>acute phase proteins</term></item><item><term>leukopenia</term></item><item><term>CD4-neutrophil</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996-10-08">Modified</change><change when="1997">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JVAC</jid><aid>96002320</aid><ce:pii>S0264-410X(96)00232-0</ce:pii><ce:doi>10.1016/S0264-410X(96)00232-0</ce:doi><ce:copyright type="unknown" year="1997"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</ce:title><ce:author-group><ce:author><ce:given-name>Terecita D.</ce:given-name><ce:surname>Yule</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Mark B.</ce:given-name><ce:surname>Roth</ce:surname></ce:author><ce:author><ce:given-name>Kimberly</ce:given-name><ce:surname>Dreier</ce:surname></ce:author><ce:author><ce:given-name>Anthony F.</ce:given-name><ce:surname>Johnson</ce:surname></ce:author><ce:author><ce:given-name>Melissa</ce:given-name><ce:surname>Palmer-Densmore</ce:surname></ce:author><ce:author><ce:given-name>Kris</ce:given-name><ce:surname>Simmons</ce:surname></ce:author><ce:author><ce:given-name>Robert</ce:given-name><ce:surname>Fanton</ce:surname></ce:author><ce:affiliation><ce:textfn>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>To whom correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="5" month="7" year="1996"></ce:date-received><ce:date-revised day="8" month="10" year="1996"></ce:date-revised><ce:date-accepted day="8" month="10" year="1996"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>canine parvovirus vaccine</ce:text></ce:keyword><ce:keyword><ce:text>acute phase proteins</ce:text></ce:keyword><ce:keyword><ce:text>leukopenia</ce:text></ce:keyword><ce:keyword><ce:text>CD4-neutrophil</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title></titleInfo><name type="personal"><namePart type="given">Terecita D.</namePart><namePart type="family">Yule</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><description>To whom correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark B.</namePart><namePart type="family">Roth</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kimberly</namePart><namePart type="family">Dreier</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony F.</namePart><namePart type="family">Johnson</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Melissa</namePart><namePart type="family">Palmer-Densmore</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kris</namePart><namePart type="family">Simmons</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert</namePart><namePart type="family">Fanton</namePart><affiliation>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1997</dateIssued><dateModified encoding="w3cdtf">1996-10-08</dateModified><copyrightDate encoding="w3cdtf">1997</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.</abstract><note type="content">Section title: Paper</note><subject><genre>Keywords</genre><topic>canine parvovirus vaccine</topic><topic>acute phase proteins</topic><topic>leukopenia</topic><topic>CD4-neutrophil</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1997</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0039-4</identifier><part><date>1997</date><detail type="volume"><number>15</number><caption>vol.</caption></detail><detail type="issue"><number>6–7</number><caption>no.</caption></detail><extent unit="issue-pages"><start>587</start><end>783</end></extent><extent unit="pages"><start>720</start><end>729</end></extent></part></relatedItem><identifier type="istex">ED82901CC45CF7E00C6B3215F1A3E36841490C1F</identifier><identifier type="ark">ark:/67375/6H6-3H03FGMF-Q</identifier><identifier type="DOI">10.1016/S0264-410X(96)00232-0</identifier><identifier type="PII">S0264-410X(96)00232-0</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000804 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000804 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:ED82901CC45CF7E00C6B3215F1A3E36841490C1F
|texte= Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease
}}
| This area was generated with Dilib version V0.6.33. |  |